P/E ratio for Evolent Health (EVH)
P/E ratio as of June 2024 (TTM): -30.8
According to Evolent Health's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -30.7571. At the end of 2022 the company had a P/E ratio of -140.
P/E ratio history for Evolent Health from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -140 | 123.26% |
| 2021 | -62.9 | 1437.83% |
| 2020 | -4.09 | 64.02% |
| 2019 | -2.49 | -91.5% |
| 2018 | -29.3 | 133.75% |
| 2017 | -12.6 | 213.78% |
| 2016 | -4.00 | -924.78% |
| 2015 | 0.4850 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 National Healthcare
NHC | 50.9 | -265.44% | 🇺🇸 USA |
 Global Cord Blood CORBF | 1.74 | -105.67% | 🇭🇰 Hong Kong |
 Graham Holdings GHC | 22.4 | -172.93% | 🇺🇸 USA |
 CryoLife CRY | N/A | N/A | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.